WADA Peptide List 2026: What Athletes Need to Know

Why This Article Exists

The peptide space has a communications problem. Vendors sell research peptides to athletes with no discussion of anti-doping rules. Coaches recommend recovery peptides without checking the Prohibited List. Athletes use BPC-157 or TB-500 for rehabilitation — substances that are unambiguously banned by WADA — because they read that the substances are "legal" in a general consumer sense and assumed that meant "fine for competing athletes."

It does not. "Legal to possess" and "permitted under anti-doping rules" are completely different categories. A substance can be legal to buy in your country and simultaneously be a career-ending anti-doping violation. This article covers exactly where peptides fall under WADA's 2026 Prohibited List, which testing windows apply, whether TUEs are available, and what the practical stakes are for athletes at every level.

WADA's Classification System, Explained

The World Anti-Doping Agency publishes its Prohibited List annually, effective January 1. The 2026 list is the governing document for all athletes who compete under sports organizations that have adopted the WADA Code — which includes all Olympic and Paralympic federations, most national leagues, and most major professional sports bodies.

The list is organized into three sections:

• Substances and methods prohibited at all times: Classes S0 through S5 and Methods M1 through M3. These apply in-competition AND out-of-competition. An athlete can test positive during off-season, during rehabilitation, or at training camp — not just on competition day.
• Substances prohibited in-competition only: Classes S6 through S9. These apply only during the competition period as defined by each sport's governing body (typically 12–48 hours before competition through end of competition).
• Substances prohibited in particular sports: Class P1 — beta-blockers prohibited in sports requiring precision (archery, shooting, some equestrian events).

For peptides, the relevant categories are S0 and S2. Both are prohibited at all times.

WADA Class	Category Name	Prohibited When	Relevant to Peptides?
S0	Non-Approved Substances	At all times	Yes — BPC-157, AOD-9604, any unapproved pharmacological substance
S1	Anabolic Agents	At all times	Partial — some SARMs; not classic peptides
S2	Peptide Hormones, Growth Factors, Related Substances	At all times	Yes — GHRPs, IGF-1, TB-500, follistatin, GH mimetics
S3	Beta-2 Agonists	At all times	No
S4	Hormone and Metabolic Modulators	At all times	Partial — some SERM/aromatase inhibitors
S5	Diuretics and Masking Agents	At all times	No

Section S0: Non-Approved Substances — The Catch-All

S0 is the most sweeping category on WADA's list. It prohibits any pharmacological substance that is not currently approved by any governmental regulatory authority for human therapeutic use — anywhere in the world.

This means that if a substance has no approved medical indication in any country — no FDA approval, no EMA approval, no Health Canada approval, no TGA approval — it automatically qualifies as an S0 prohibited substance for competing athletes. No specific listing by name is required, though WADA does name specific examples for clarity.

BPC-157 is explicitly named under S0. WADA added BPC-157 to its Prohibited List in 2022. It has no approved medical use anywhere in the world. Athletes competing under WADA-compliant organizations are prohibited from using BPC-157 at all times — in-season, off-season, during rehabilitation, during training camps.

AOD-9604 is also named under S0. Originally developed as a potential anti-obesity compound derived from the C-terminus of human growth hormone, AOD-9604 never received regulatory approval and is prohibited under S0.

The practical implication of S0 is that most research peptides without a specific clinical approval automatically fall into the prohibited category. Athletes should not assume a peptide is permissible simply because it is not named on a specific list — the S0 catch-all covers the entire category of non-approved substances.

Section S2: Peptide Hormones, Growth Factors, and Related Substances

S2 is where the most performance-relevant peptides sit. WADA prohibits the following substance classes under S2, all at all times:

S2 Subcategory	Specific Peptides	Common Use Case
Erythropoiesis-stimulating agents (ESAs)	EPO, CERA, darbepoetin, hematide	Endurance performance
Peptide hormones and their releasing factors	LH, FSH, hCG, GnRH analogues, CRF	Endocrine manipulation
Growth hormone (GH) and releasing factors	Recombinant GH, GHRFs (CJC-1295, sermorelin), GHRPs (GHRP-2, GHRP-6, ipamorelin, hexarelin, pralmorelin)	Muscle gain, recovery, fat loss
Insulin-like growth factors	IGF-1 and analogues: Long R3 IGF-1, des(1-3) IGF-1, MGF (mechano growth factor), PEG-MGF	Muscle hypertrophy, recovery
Thymosin Beta-4 and releasing factors	TB-500 (synthetic TB-4), TB-4 fragments	Injury recovery, wound healing
Fibroblast growth factors (FGFs)	FGF-1, FGF-2 and analogues	Tissue repair, angiogenesis
Hepatocyte growth factors (HGFs)	HGF and analogues	Tissue repair
Platelet-derived growth factors (PDGFs)	PDGF-BB and analogues	Tissue healing
Vascular endothelial growth factors (VEGFs)	VEGF-A, VEGF-B, VEGF-C	Angiogenesis, endurance
Follistatin, myostatin inhibitors	Follistatin, myostatin antibodies, activin receptor blockers	Muscle mass
GH secretagogues / mimetics	MK-677 (ibutamoren), anamorelin and analogues	GH stimulation, muscle, recovery

TB-500: The Recovery Peptide With No Safe Harbor

TB-500 is the commercial brand name for synthetic Thymosin Beta-4, a naturally occurring 43-amino-acid peptide involved in actin regulation, wound healing, and inflammation modulation. It has attracted significant interest in the athletic community as a recovery accelerator for tendon, muscle, and connective tissue injuries.

WADA explicitly names Thymosin Beta-4 and its releasing factors under S2. The agency has also confirmed that synthetic fragments of TB-4 are covered by this prohibition. Athletes purchasing TB-500 from research chemical vendors should understand it is unambiguously prohibited. There is no gray area here, no interpretation issue, and no TUE pathway — TB-500 has no approved medical indication, and there is no clinical application for which an exemption could be granted.

GHRPs: GHRP-2, GHRP-6, Ipamorelin, Hexarelin

Growth hormone-releasing peptides are prohibited under S2 as GH releasing factors. All of the following are banned at all times:

• GHRP-2 (pralmorelin): Approved as a diagnostic agent in some countries; the approval does not create a TUE pathway for athletic use.
• GHRP-6: No approved use; prohibited under S2.
• Ipamorelin: No approved use; prohibited under S2.
• Hexarelin: No approved use; prohibited under S2.
• CJC-1295 / Sermorelin: GHRH analogues; prohibited under S2 as GH releasing factors. Sermorelin has limited approved use in some countries for GH deficiency diagnostics — this does not create a TUE pathway for recovery or performance applications.

IGF-1 and MGF

Insulin-like growth factor 1 (IGF-1) and its analogues — including Long R3 IGF-1, des(1-3) IGF-1, mechano growth factor (MGF), and PEG-MGF — are prohibited under S2. Recombinant IGF-1 (mecasermin, marketed as Increlex) has an approved medical use for severe primary IGF-1 deficiency in children. A TUE for this specific, documented medical condition is theoretically possible — but the dosing, indication, and monitoring requirements would bear no resemblance to the research use context. There is no TUE pathway for IGF-1 for performance or recovery purposes.

In-Competition vs. Out-of-Competition: What Athletes Get Wrong

A persistent misunderstanding in the athletic community is that peptides used only during off-season or rehabilitation are safe from WADA sanctions. This is incorrect for S0 and S2 class substances.

S0, S1, S2, S3, S4, and S5 are prohibited at all times — meaning out-of-competition testing is authorized and positive results carry full sanctions. An athlete who uses TB-500 during the off-season for a knee rehabilitation program and is randomly tested six months before competition can face the same sanctions as an athlete caught doping on competition day.

Substance	WADA Class	In-Competition?	Out-of-Competition?
BPC-157	S0	Prohibited	Prohibited
TB-500 / Thymosin Beta-4	S2	Prohibited	Prohibited
GHRP-2, GHRP-6, ipamorelin	S2	Prohibited	Prohibited
IGF-1, MGF, Long R3 IGF-1	S2	Prohibited	Prohibited
Recombinant growth hormone	S2	Prohibited	Prohibited
AOD-9604	S0	Prohibited	Prohibited
Follistatin	S2	Prohibited	Prohibited
MK-677 (ibutamoren)	S2	Prohibited	Prohibited
GHK-Cu (copper peptide)	Not currently listed	Not explicitly prohibited*	Not explicitly prohibited*

*GHK-Cu (glycyl-L-histidyl-L-lysine copper) is a naturally occurring tripeptide not currently named on WADA's Prohibited List. However, S0 broadly covers any pharmacological substance not approved by a regulatory authority — athletes with WADA obligations should consult their national anti-doping organization before use.

TUEs: Can Athletes Get Exemptions for Peptides?

A Therapeutic Use Exemption (TUE) is a formal process by which an athlete with a genuine medical need may receive authorization to use a prohibited substance. TUEs are granted when four conditions are met:

1. The athlete would experience significant health impairment if denied the prohibited substance.
2. The therapeutic use is unlikely to produce additional enhancement of performance beyond the return to normal health.
3. There is no reasonable permitted therapeutic alternative.
4. The necessity for use is not a consequence of prior prohibited substance use.

For most research peptides, TUEs are unavailable in practice because they fail conditions 1 and 3. A substance with no approved medical indication has no established therapeutic dose, no documented clinical safety profile, and no recognized medical condition it treats. A physician cannot prescribe it as a medical treatment — because it has no approved treatment use.

Peptide	Approved Medical Use?	TUE Available?	Notes
BPC-157	No	No	No approved indication anywhere in the world; S0 prohibition
TB-500	No	No	No approved indication; S2 prohibition
GHRP-2 (pralmorelin)	Diagnostic use only (limited)	No (for performance)	Diagnostic approval does not extend to recovery or athletic use
Sermorelin / CJC-1295	Limited (GH deficiency diagnosis)	No (for recovery use)	Diagnostic indication only; does not support TUE for recovery
Recombinant IGF-1 (Increlex)	Yes — severe primary IGF-1 deficiency in children	Theoretically possible	Requires documented IGF-1 deficiency; strict criteria; no recovery use
Recombinant GH	Yes — GH deficiency, Turner syndrome, others	Yes — with documented deficiency	Strictly monitored; doses far below "research use" doses; not for athletic recovery
AOD-9604	No	No	Phase 3 trials failed; never approved; S0 prohibition

The bottom line: athletes hoping to use peptides for legitimate injury rehabilitation under a TUE will find the pathway blocked for all the commonly researched compounds. The substances athletes tend to use for recovery (BPC-157, TB-500, GHRPs) are precisely the ones with no approved medical use and therefore no TUE availability.

Which Anti-Doping Agencies Follow WADA

WADA's Prohibited List applies to all sports organizations and athletes who have signed the WADA Code. In practice, this is nearly universal across organized international sport:

• USADA (United States Anti-Doping Agency) — governs US Olympic, Paralympic, and many professional athletes. Has explicitly noted BPC-157 positives in recent athlete sanctions.
• UKAD (UK Anti-Doping) — governs UK-based athletes across all Olympic sports and many professional leagues.
• ASADA (Australian Sports Anti-Doping Authority) — strictly enforces the WADA code with active out-of-competition testing programs. Australia has been a leading enforcer of peptide-related violations.
• CCES (Canadian Centre for Ethics in Sport) — governs Canadian Olympic and national sport athletes.
• All 206 National Olympic Committees — bound by the WADA Code through the IOC.
• International sport federations — FIFA (football), World Athletics, UCI (cycling), World Aquatics, etc. — all adopt the WADA code and Prohibited List directly.

Major US professional leagues are not WADA signatories but maintain their own anti-doping programs, some of which are aligned with WADA standards. NFL players are tested under a joint NFL/NFLPA policy. MLB has an independent drug program. NBA has its own testing protocol. Athletes in these leagues should verify their specific league policy — while WADA's Prohibited List is not binding, many of the same substances are prohibited under league rules.

College athletes in the United States fall under NCAA jurisdiction. The NCAA Banned Substances List overlaps significantly with WADA's — all GH secretagogues, peptide hormones, and growth factors are prohibited by the NCAA as well.

What This Means For Athletes

If you are a competing athlete subject to WADA or NCAA testing

The answer is simple and absolute: BPC-157, TB-500, all GHRPs, IGF-1 analogues, and AOD-9604 are off the table — during competition, during off-season, during rehabilitation, and during training camps. There is no safe window. There is no TUE pathway for any of these. "Research use only" labeling on vendor products is not a defense against a positive test. The "my doctor recommended it" explanation holds no weight when the substance is not approved for therapeutic use anywhere in the world.

Athletes who have been told by coaches, trainers, or health practitioners that these peptides are "legal" may be receiving accurate information about personal possession laws — but that has nothing to do with anti-doping rules. Make the distinction clearly, and verify any recovery supplement against the WADA Prohibited List or your sport's governing body before use.

If you are a recreational athlete or fitness participant not subject to formal testing

WADA rules do not apply to you. The regulatory questions are different: whether a substance is legal to possess, whether it carries health risks, and whether the research evidence supports the claimed benefit. Those questions are what the rest of this site covers. But if you compete in organized sport — at any level, in any federation that has adopted the WADA Code — check before you assume.

If you are a coach, trainer, or team physician

Recommending or supplying prohibited substances to athletes creates liability under the WADA Code's "entourage" provisions. Support personnel — coaches, doctors, nutritionists, and trainers — can face sanctions, including bans from sport, for facilitating doping. Recommending BPC-157 or TB-500 to a competing athlete is not a gray area — it is facilitating a violation of the WADA Code, regardless of the substance's general legal status.

The safest protocol is to verify any recovery supplement or therapeutic peptide against the WADA Prohibited List before recommending it to athletes under your supervision. WADA maintains a substance search tool at its website; USADA maintains a similar resource for US athletes.

How WADA Updates the Prohibited List

WADA updates its Prohibited List annually, effective January 1. The update cycle:

• Q1–Q2: WADA receives nominations for additions, removals, or reclassifications from national anti-doping organizations, sport federations, and the scientific community.
• Q2–Q3: WADA's List Committee evaluates submissions, reviews scientific evidence, and deliberates on changes. Criteria for prohibition: performance-enhancing potential, health risk, or violation of the spirit of sport (two of three required).
• September: Draft list published for stakeholder review and comment.
• October: Final list published.
• January 1: New list takes effect.

Athletes who use peptides close to a regulatory gray area should monitor the September publication each year. A substance that was not explicitly prohibited may be added in the next annual cycle — and once a substance is on the list effective January 1, there is no grace period for athletes who had not yet cleared it from their system.

Related Reading

For the regulatory picture outside anti-doping: BPC-157 Legal Status 2026: FDA, Compounding, and What You Need to Know — covers the FDA timeline (Category 1 → Category 2 ban → PCAC July 2026 review), gray-market sourcing risks, and the global country-by-country legal status. For the research evidence on BPC-157: BPC-157 Benefits: What the Research Actually Shows and the BPC-157 recovery protocol overview.